Products
Vilamakitug Biosimilar Monoclonal Antibody (IL-1α) for Research
Cat No.: GMP-Bios-INN-1457
Anti-IL1A therapeutic antibody (Pre-made Vilamakitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Vilamakitug (development codes Natrunix/XB-2001) is a monoclonal antibody targeting interleukin-1 alpha (IL-1A). It is developed by XBiotech USA, Inc for Pancreatic cancer, Arthritis, Colorectal cancer in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1457-1mg | 1mg | 3090 |
| GMP-Bios-INN-1457-10mg | 10mg | |
| GMP-Bios-INN-1457-100mg | 100mg | |
| GMP-Bios-INN-1457-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Vilamakitug biosimilar, Whole mAb, Anti-IL1A Antibody: Anti-IL1/IL-1A/IL1F1/IL1-ALPHA therapeutic antibody |
| INN Name | Vilamakitug |
| Target | IL1A |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | XBiotech USA; Inc |
| Conditions Approved | na |
| Conditions Active | Pancreatic cancer;Arthritis;Colorectal cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
